The BVN™ system is an adjunct to hand-held ultrasound to assist the health care providers trained in breast ultrasound in their scanning process. The BVN™ system will add multiple important aspects to current ultrasound including coverage mapping of scanned area, precision mapping of areas of interest for diagnostic analysis and relocation. In addition, the BVN™ system helps remove inter-operator variability that exists today and limits wide use of ultrasound for breast cancer care.
“We are thrilled to receive our 510(k) clearance from the FDA for our innovative system, and we look forward to bringing groundbreaking technology to the medical community and to improving patients’ lives.” said Dr. Calin Caluser, President and Founder, MetriTrack.
MetriTrack’s BVN™ model G-2000 is FDA cleared and available for purchase and installation. Please visit our website www.MetriTrack.com, email us at firstname.lastname@example.org or call us at (708) 498-3578 to learn more or to schedule a demo.
Hillside, IL based MetriTrack Inc. was established in 2014 by Dr. Calin Caluser, a practicing breast radiologist. MetriTrack is developing novel technologies for improving the clinical effectiveness and utilization of ultrasound as the preferred modality for imaging of dense breast tissue. With the MetriTrack technology, ultrasound can provide more utilization in the detection and subsequent treatment of small breast cancers. MetriTrack has FDA clearance for its BVN G-2000 system, was awarded an NIH SBIR Phase I grant, presented, and published about its innovative technology at many international meetings and was granted multiple US and international patents.
For more information, please visit www.metritrack.com.